All Stories

  1. An update on pharmacotherapies and emerging therapeutic approaches for geographic atrophy
  2. A theoretical model for the influence of age, race and ethnicity on retinal mitochondria dysfunction
  3. Gene therapy and cost-effectiveness analysis: Current issues and future research
  4. Gene-Agnostic Therapeutic Strategies for Inherited Retinal Diseases: Neuroprotection and Immunomodulation
  5. Biological therapies at 25 years: from incremental advances to revolutionary transformations
  6. Modeling the relation between intraocular pressure and human trabecular meshwork fluid-mechanical properties
  7. Thyroid eye disease: revolutionizing treatment with IGF-1 receptor targeted therapy
  8. Beyond the injection: delivery systems reshaping retinal disease management
  9. Autoimmune neuro-ophthalmic disorders: pathophysiologic mechanisms and targeted biologic therapies
  10. Spectral-domain OCT characteristics of intraretinal hyper-reflective foci associated with age-related macular degeneration and diabetic retinopathy
  11. Suprachoroidal drug delivery: a versatile therapeutic platform
  12. Three-Year Clinical Outcomes in Geographic Atrophy: An Analysis of 18,712 Patient Eyes
  13. Long-acting delivery and therapies for neovascular age-related macular degeneration
  14. Safety and Tolerability of Suprachoroidal Axitinib, CLS-AX, for Neovascular AMD; Phase 1/2a Open-Label, Dose-Escalation Trial
  15. Gene Therapy for Non-Hereditary Retinal Disease: Age-Related Macular Degeneration, Diabetic Retinopathy, and Beyond
  16. SUPRACHOROIDAL SPACE INJECTION TECHNIQUE
  17. Suprachoroidal Drug Delivery for Macular Edema Associated With Noninfectious Uveitis
  18. Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy
  19. Safety and Efficacy of CLS-TA by Anatomic Location of Inflammation: Results from the Phase 3 PEACHTREE Clinical Trial
  20. Effect of Race and Insurance Status on Treatment and Outcomes in Diabetic Retinopathy: Analysis of 43 274 Eyes Using the IRIS Registry
  21. The complement system: a novel therapeutic target for Age-related macular degeneration
  22. The evolving therapeutic landscape of diabetic retinopathy
  23. Prediction for 2-Year Vision Outcomes Using Early Morphologic and Functional Responses in the Comparison of Age-related Macular Degeneration Treatments Trials
  24. Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial
  25. Optical coherence tomography outcomes as biomarkers for disease status, visual function, and prognosis in diabetic macular edema
  26. Suprachoroidal triamcinolone acetonide injectable suspension for macular edema associated with noninfectious uveitis: an in-depth look at efficacy and safety
  27. Aging Effects on Optic Nerve Neurodegeneration
  28. Anatomic Biomarkers of Macular Edema Associated with Retinal Vein Occlusion
  29. Triamcinolone Acetonide Suprachoroidal Injectable Suspension for Uveitic Macular Edema: Integrated Analysis of Two Phase 3 Studies
  30. Microinjection via the suprachoroidal space: a review of a novel mode of administration
  31. Advancements in ocular gene therapy delivery: vectors and subretinal, intravitreal, and suprachoroidal techniques
  32. Predominantly Persistent Intraretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments Trials
  33. Suprachoroidal delivery enables targeting, localization and durability of small molecule suspensions
  34. Progress in the pharmacotherapy of uveitis: the art of personalized care
  35. Molecular Genetic Mechanisms in Age-Related Macular Degeneration
  36. Suprachoroidal Drug Delivery for Clinicians: Anatomic Principles, Clinical Data in Uveitis, and Future Directions
  37. Baseline Characteristics and Outcomes After Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion
  38. Thiazolidinedione use and retinal fluid in the comparison of age-related macular degeneration treatments trials
  39. Suprachoroidal Injection of Triamcinolone Acetonide Suspension: Ocular Pharmacokinetics and Distribution in Rabbits Demonstrates High and Durable Levels in the Chorioretina
  40. Longer-Term Anti-VEGF Therapy Outcomes in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Vein Occlusion-Related Macular Edema
  41. A randomized, double-masked, multicenter trial of topical acrizanib (LHA510), a tyrosine kinase VEGF-receptor inhibitor, in treatment-experienced subjects with neovascular age-related macular degeneration
  42. Challenges of Cost-Effectiveness Analyses of Novel Therapeutics for Inherited Retinal Diseases
  43. Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications
  44. Disease Progression Pathways of Wet AMD: Opportunities for New Target Discovery
  45. Intraocular Pressure–Related Events After Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion
  46. Suprachoroidal CLS‐TA versus Rescue Therapies for the Treatment of Uveitic Macular Edema: A Post Hoc Analysis of PEACHTREE
  47. OCT Anatomic and Temporal Biomarkers in Uveitic Macular Edema
  48. Genes and Gene Therapy in Inherited Retinal Disease
  49. Preface to DNA-based and RNA-based Gene Therapies in Ophthalmology: Inherited and Noninherited Retinal Disorders
  50. RPE65 Mutation-associated Inherited Retinal Disease and Gene Therapies
  51. Suprachoroidal CLS-TA with and without Systemic Corticosteroid and/or Steroid-Sparing Therapy: A Post-Hoc Analysis of the Phase 3 PEACHTREE Clinical Trial
  52. Genetics of Diabetic Retinopathy, a Leading Cause of Irreversible Blindness in the Industrialized World
  53. Glaucoma Heritability: Molecular Mechanisms of Disease
  54. DNA- and RNA-based Gene Therapies in Ophthalmology
  55. Delivery of Genetic Information: Viral Vector and Nonviral Vector Gene Therapies
  56. Diabetic Retinopathy in the Aging Population: A Perspective of Pathogenesis and Treatment
  57. Host Immune Responses after Suprachoroidal Delivery of AAV8 in Nonhuman Primate Eyes
  58. Preface
  59. Visual Acuity in Retinal Vein Occlusion, Diabetic, and Uveitic Macular Edema
  60. Evaluation of Long-Lasting Potential of Suprachoroidal Axitinib Suspension Via Ocular and Systemic Disposition in Rabbits
  61. Physics-based modeling of Age-related Macular Degeneration—A theoretical approach to quantify retinal and choroidal contributions to macular oxygenation
  62. Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA)
  63. Understanding the genetic pathology of Stargardt disease: a review of current findings and challenges
  64. Suprachoroidal Delivery of Small Molecules, Nanoparticles, Gene and Cell Therapies for Ocular Diseases
  65. Suprachoroidal CLS-TA for non-infectious uveitis: an open-label, safety trial (AZALEA)
  66. Biomechanics of suprachoroidal drug delivery: From benchtop to clinical investigation in ocular therapies
  67. Genetic Testing Prevalence, Guidelines, and Pitfalls in Large, University-Based Medical Systems
  68. Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema
  69. Molecular Genetics of Glaucoma: Subtype and Ethnicity Considerations
  70. Suprachoroidally Delivered DNA Nanoparticles Transfect Retina and Retinal Pigment Epithelium/Choroid in Rabbits
  71. RNA Therapeutics for Retinal Diseases
  72. Clinical Characterization of Suprachoroidal Injection Procedure Utilizing a Microinjector across Three Retinal Disorders
  73. Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes
  74. Microbial Spectrum and Antibacterial Susceptibility of Endophthalmitis Cultures in a Tertiary Referral Center in the Midwestern United States: An Analysis From 295 Patients
  75. Anti-Integrin therapy for retinovascular diseases
  76. Evolution of Primary Scleral Buckling Surgery: A Modified Lean Six Sigma Technique to Improve Surgical Efficiency
  77. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes
  78. Suprachoroidal Delivery of Viral and Nonviral Gene Therapy for Retinal Diseases
  79. Retinal oximetry in glaucoma: investigations and findings reviewed
  80. Voretigene neparvovec-rzyl for treatment of RPE65-mediated inherited retinal diseases: a model for ocular gene therapy development
  81. Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment
  82. Visual Acuity Outcomes and Anti–Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients
  83. Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis
  84. Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review
  85. Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Inherited Retinal Disease
  86. Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease
  87. Important Considerations in Modeling the Cost-Effectiveness for the First Food and Drug Administration–Approved Gene Therapy and Implications for Future One-Time Therapies
  88. Efficacy and safety of bromfenac 0.075% formulated in DuraSite for pain and inflammation in cataract surgery
  89. Innovative therapies for neovascular age-related macular degeneration
  90. Vascular dysfunction in retinitis pigmentosa
  91. Complement inhibition as a therapeutic strategy in retinal disorders
  92. Estimation of impact of RPE65-mediated inherited retinal disease on quality of life and the potential benefits of gene therapy
  93. Pathological Consequences of Vascular Alterations in the Eye
  94. Vitreous Pathology
  95. Vitreous Physiology
  96. Real-world Outcomes of Anti–Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema in the United States
  97. Vital Dyes in Vitreomacular Surgery
  98. Stargardt macular dystrophy and evolving therapies
  99. Real-world Outcomes of Anti–Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration in the United States
  100. The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: A review
  101. Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti–Vascular Endothelial Growth Factor Medications
  102. Pharmacotherapy of retinal disease with visual cycle modulators
  103. Gene therapy for inherited retinal and optic nerve degenerations
  104. Treatment Burden in Neovascular AMD:Visual Acuity Outcomes are Associated With Anti-VEGF Injection Frequency
  105. Gene therapy for age-related macular degeneration
  106. Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration
  107. LEAN SIX SIGMA TECHNIQUES TO IMPROVE OPHTHALMOLOGY CLINIC EFFICIENCY
  108. Induced pluripotent stem cell-based therapy for age-related macular degeneration
  109. Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration
  110. EFFICACY OF DEXAMETHASONE INTRAVITREAL IMPLANT FOR REFRACTORY MACULAR EDEMA CAUSED BY RETINAL VEIN OCCLUSION
  111. RANIBIZUMAB FOR DIABETIC MACULAR EDEMA REFRACTORY TO MULTIPLE PRIOR TREATMENTS
  112. Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials
  113. Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)
  114. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy
  115. Incidence, Risk Factors, and Timing of Elevated Intraocular Pressure After Intravitreal Triamcinolone Acetonide Injection for Macular Edema Secondary to Retinal Vein Occlusion
  116. Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials
  117. Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials
  118. Outcomes of Eyes with Lesions Composed of >50% Blood in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)
  119. Efficacy of Intravitreal Ocriplasmin for Treatment of Vitreomacular Adhesion
  120. Sustained Delivery Fluocinolone Acetonide Vitreous Implants
  121. Comparison of Optical Coherence Tomography Assessments in the Comparison of Age-Related Macular Degeneration Treatments Trials
  122. The Prevalence and Incidence of Epiretinal Membranes in Eyes With Inactive Extramacular CMV Retinitis
  123. Sporadic Visual Acuity Loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)
  124. VEGFAandVEGFR2Gene Polymorphisms and Response to Anti–Vascular Endothelial Growth Factor Therapy
  125. Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant
  126. Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab
  127. Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration
  128. Dexamethasone Intravitreal Implant in Combination with Laser Photocoagulation for the Treatment of Diffuse Diabetic Macular Edema
  129. Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials
  130. Exploratory Analysis of the Effect of Intravitreal Ranibizumab or Triamcinolone on Worsening of Diabetic Retinopathy in a Randomized Clinical Trial
  131. Comparison of Treatment Regimens for Cytomegalovirus Retinitis in Patients with AIDS in the Era of Highly Active Antiretroviral Therapy
  132. Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration
  133. Aqueous Levels of Fluocinolone Acetonide after Administration of Fluocinolone Acetonide Inserts or Fluocinolone Acetonide Implants
  134. Ranibizumab for Edema of the Macula in Diabetes Study
  135. Non-cytomegalovirus Ocular Opportunistic Infections in Patients With Acquired Immunodeficiency Syndrome
  136. Ranibizumab Versus Photodynamic Therapy for Presumed Ocular Histoplasmosis Syndrome
  137. Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration
  138. Enzymatic Vitreolysis with Ocriplasmin for Vitreomacular Traction and Macular Holes
  139. Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
  140. Incidence of Cytomegalovirus Retinitis in the Era of Highly Active Antiretroviral Therapy
  141. Impaired ocular blood flow regulation in patients with open-angle glaucoma and diabetes
  142. Evaluation of the United States Public Health Service Guidelines for Discontinuation of Anticytomegalovirus Therapy After Immune Recovery in Patients With Cytomegalovirus Retinitis
  143. Changes in Vision- and Health-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Pegaptanib Sodium or Sham
  144. Primary Endpoint Results of a Phase II Study of Vascular Endothelial Growth Factor Trap-Eye in Wet Age-related Macular Degeneration
  145. A Phase 2/3, Multicenter, Randomized, Double-Masked, 2-Year Trial of Pegaptanib Sodium for the Treatment of Diabetic Macular Edema
  146. Association of Host Genetic Risk Factors With the Course of Cytomegalovirus Retinitis in Patients Infected With Human Immunodeficiency Virus
  147. Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
  148. Patient preferences in the treatment of diabetic retinopathy
  149. Long-term Benefit of Sustained-Delivery Fluocinolone Acetonide Vitreous Inserts for Diabetic Macular Edema
  150. Ranibizumab for Choroidal Neovascularization Secondary to Causes Other Than Age-Related Macular Degeneration: A Phase I Clinical Trial
  151. Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study
  152. Course of Cytomegalovirus Retinitis in the Era of Highly Active Antiretroviral Therapy: Five-Year Outcomes
  153. Excess Mortality in Patients with AIDS in the Era of Highly Active Antiretroviral Therapy: Temporal Changes and Risk Factors
  154. Sustained Ocular Delivery of Fluocinolone Acetonide by an Intravitreal Insert
  155. Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema
  156. Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion
  157. Ranibizumab for Macular Edema following Central Retinal Vein Occlusion
  158. Response to: Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion by Schroff et al.,
  159. Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process
  160. Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up
  161. INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO PRESUMED OCULAR HISTOPLASMOSIS SYNDROME
  162. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study
  163. SCORE Study Report 7: Incidence of Intravitreal Silicone Oil Droplets Associated With Staked-on vs Luer Cone Syringe Design
  164. A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Observation to Treat Vision Loss Associated With Macular Edema Secondary to Central Retinal Vein Occlusion
  165. A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Standard Care to Treat Vision Loss Associated With Macular Edema Secondary to Branch Retinal Vein Occlusion
  166. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration
  167. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration
  168. Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
  169. Age-related macular degeneration and the aging eye
  170. Optical Coherence Tomography Measurements and Analysis Methods in Optical Coherence Tomography Studies of Diabetic Macular Edema
  171. Therapeutic effects of ranibizumab in neovascular age-related macular degeneration
  172. How the diabetic eye loses vision
  173. The Relationship Between Retrobulbar and Choroidal Hemodynamics in Non-Neovascular Age-Related Macular Degeneration
  174. Squalamine lactate for the treatment of age-related macular degeneration
  175. Ranibizumab
  176. SUSTAINED RESPONSE TO MULTIPLE INTRAVITREAL TRIAMCINOLONE ACETONIDE INJECTIONS IN A PATIENT WITH PREDOMINANTLY OCCULT CHOROIDAL NEOVASCULARIZATION
  177. Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration
  178. Corticosteroids as Antiangiogenic Agents
  179. Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration
  180. Retinal and Choroidal Blood Flow in Health and Disease
  181. ORAL ADMINISTRATION OF LUMIRACOXIB REDUCES CHOROIDAL NEOVASCULAR MEMBRANE DEVELOPMENT IN THE RAT LASER-TRAUMA MODEL
  182. HUMAN VITREOUS DISTRIBUTION OF LINEZOLID AFTER A SINGLE ORAL DOSE
  183. Anastomotic Vessels Remain Viable after Photodynamic Therapy in Primate Models of Choroidal Neovascularization
  184. Erratum
  185. New and classic insights into presumed ocular histoplasmosis syndrome and its treatment
  186. Current and future pharmacological intervention for diabetic retinopathy
  187. Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration
  188. MV-6401, a potent photosensitizer: a review of the current state of photosensitizing agents for the treatment of exudative age-related macular degeneration
  189. Photodynamic therapy with PhotoPoint photosensitiser MV6401, indium chloride methyl pyropheophorbide, achieves selective closure of rat corneal neovascularisation and rabbit choriocapillaris
  190. Pharmacotherapy for diabetic retinopathy
  191. Macular pigment density and aging, assessed in the normal elderly and those with cataracts and age-related macular degeneration
  192. EVALUATION OF PHOTOPOINT PHOTOSENSITIZER MV6401, INDIUM CHLORIDE METHYL PYROPHEOPHORBIDE, AS A PHOTODYNAMIC THERAPY AGENT IN PRIMATE CHORIOCAPILLARIS AND LASER-INDUCED CHOROIDAL NEOVASCULARIZATION
  193. Corticosteroids in posterior segment disease: an update on new delivery systems and new indications
  194. Laser trabecular sclerosis for chronic hypotony after vitreoretinal surgery
  195. The Squirrel Monkey: Characterization of a New-World Primate Model of Experimental Choroidal Neovascularization and Comparison with the Macaque
  196. Diagnostic Imaging of Retinal Disease
  197. Current and Future Treatment Options for Nonexudative and Exudative Age-Related Macular Degeneration
  198. Squalamine Lactate Reduces Choroidal Neovascularization in a Laser-Injury Model in the Rat
  199. Diabetic Retinopathy and Diabetic Macular Edema: Pathophysiology, screening, and novel therapies
  200. Bacterial endophthalmitis prophylaxis
  201. Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants
  202. The effects of dorzolamide on choroidal and retinal perfusion in non-exudative age related macular degeneration
  203. Leber congenital amaurosis associated with optic disk neovascularization and vitreous hemorrhage
  204. Recent advances in the treatment of exudative age-related macular degeneration, including transpupillary thermotherapy
  205. Proton therapy for exudative age-related macular degeneration: a randomized, sham-controlled clinical trial
  206. Ocular perfusion abnormalities in diabetes
  207. Novel approaches for retinal drug delivery
  208. An update on photodynamic therapy in age-related macular degeneration
  209. DIAGNOSTIC AND THERAPEUTIC CHALLENGES
  210. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration
  211. Choroidal perfusion perturbations in non-neovascular age related macular degeneration
  212. LOCALIZATION OF ROSE BENGAL, ALUMINUM PHTHALOCYANINE TETRASULFONATE, AND CHLORIN e6 IN THE RABBIT EYE
  213. Bacterial endophthalmitis prophylaxis for cataract surgery
  214. Presumed ocular histoplasmosis syndrome: update on epidemiology, pathogenesis, and photodynamic, antiangiogenic, and surgical therapies
  215. Relation between dietary intake, serum concentrations, and retinal concentrations of lutein and zeaxanthin in adults in a Midwest population
  216. Delayed suprachoroidal hemorrhage after glaucoma filtration procedures1 1The authors have no financial or proprietary interest in any aspect of this study.
  217. Evolving pathophysiological paradigms for age related macular degeneration
  218. Macular pigment optical density in a midwestern sample
  219. Ocular perfusion and age-related macular degeneration
  220. Intravitreal Triamcinolone Acetonide Inhibits Choroidal Neovascularization in a Laser-Treated Rat Model
  221. Anti-angiogenic therapy of proliferative diabetic retinopathy
  222. Potential therapeutic application of antisense oligonucleotides in the treatment of ocular diseases
  223. Changing therapeutic paradigms in CMV retinitis in AIDS
  224. Aging Affects the Retrobulbar Circulation Differently in Women and Men
  225. Endothelin-1-Mediated Retinal Artery Vasospasm and the Rabbit Electroretinogram
  226. MACULAR BUCKLING FOR RETINAL DETACHMENT DUE TO MACULAR HOLE IN HIGHLY MYOPIC EYES WITH POSTERIOR STAPHYLOMA
  227. Vasoprotection as neuroprotection for the optic nerve
  228. INTRAVITREAL TRIAMCINOLONE ACETONIDE IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION
  229. Olestra Consumption Is Not Associated with Macular Pigment Optical Density in a Cross-Sectional Volunteer Sample in Indianapolis
  230. Update on acute and chronic endophthalmitis
  231. Changing therapeutic paradigms for exudative age-related macular degeneration: antiangiogenic agents and photodynamic therapy
  232. Corticosteroids as an Antiangiogenic Agent for Histoplasmosis-Related Subfoveal Choroidal Neovascularization
  233. Color Doppler imaging discloses reduced ocular blood flow velocities in nonexudative age-related macular degeneration
  234. Mitochondrial maculopathy: geographic atrophy of the macula in the MELAS associated A to G 3243 mitochondrial DNA point mutation
  235. Ginkgo biloba Extract Increases Ocular Blood Flow Velocity
  236. Progress in measurement of ocular blood flow and relevance to our understanding of glaucoma and age-related macular degeneration
  237. Comparison of intraocular to plasma HIV-1 viral burden in patients with cytomegalovirus retinitis
  238. Regulation of Retinal and Optic Nerve Blood Flow
  239. Age-Related Macular Degeneration
  240. THE USE OF DYE DILUTION CURVE ANALYSIS IN THE QUANTIFICATION OF INDOCYANINE GREEN ANGIOGRAMS OF THE HUMAN CHOROID
  241. Correspondence
  242. Repair of retinal detachments due to Herpes varicella-zoster virus retinitis
  243. Evolution of a full-thickness macular hole
  244. Radiation Therapy For Exudative Age-Related Macular Degeneration
  245. Talc Embolism: A Static Retinopathy
  246. Vascular Endothelial Growth Factor-Induced Retinal Permeability Is Mediated by Protein Kinase C In Vivo and Suppressed by an Orally Effective  -Isoform-Selective Inhibitor
  247. EXOGENOUS ASPERGILLUS NIGER ENDOPHTHALMITIS IN A PATIENT WITH A FILTERING BLEB
  248. Surgical Treatment of a Macular Hole Secondary to Accidental Laser Burn
  249. Blebitis, Early EndophthalmitS, and Late Endophthalmitis after Glaucoma-filtering Surgery
  250. Uveal lymphoid neoplasia: A clinical-pathologic correlation and review of the early form
  251. Subretinal Aspiration Biopsy of Ocular Lymphoma
  252. Acute Progressive Multifocal Best's Disease in a 61 -year-old Man
  253. Postvitrectomy Positioning Complicated by Ulnar Nerve Palsy
  254. Ocular Antimicrobial Therapy
  255. Endophthalmitis Following Glaucoma Filtering Surgery
  256. INTRAVITREAL TOXICITY OF DENTAL ADHESIVES IN THE RABBIT
  257. Serpiginous Choroiditis
  258. SEVERE PENETRATING EYE TRAUMA CAUSED BY FISH PICK ACCIDENTS
  259. Herpes Simplex Virus Corneal Dendrite
  260. Vitreous amyloidosis in familial amyloidotic polyneuropathy. Report of a case with the Val30Met transthyretin mutation
  261. Laser photodisruption of visible retinal artery emboli.
  262. Retinal artery occlusion in rabbit eyes using human atheroma
  263. Seronegative myasthenia gravis: A plasma factor inhibiting agonist-induced acetylcholine receptor function copurifies with IgM
  264. A susceptibility locus for multiple sclerosis is linked to the T cell receptor β chain complex
  265. PHOTOSENSITIZATION OF SINGLE-STRAND BREAKS IN pBR322 DNA BY ROSE BENGAL
  266. A simple method for DNA purification from peripheral blood
  267. Molecular Genotypes of the T-Cell Receptor Beta Chain in Families with Multiple Sclerosis
  268. PHOTOADDITION OF CHLORPROMAZINE TO GUANOSINE-5'-MONOPHOSPHATE